U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794670) titled 'Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease' on Aug. 12.

Brief Summary: A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Preclinical Alzheimer's Disease

Intervention: DRUG: Obicetrapib 10 mg

once daily 10 mg Obicetrapib tablet

DRUG: Matching placebo tablets

matching placebo tablet

Recruitment Status: NOT_YET_RECRUITING

Sponsor: NewAmsterdam Pharma

Disclaimer: Curated by HT Syndication....